 One analyst is putting the odds at three to one that tests of a Karuna Therapeutics Inc. KRTX , Financial schizophrenia drug will meet study objectives, paving the way to Food and Drug Administration approval. If that happens, Jefferies analyst Chris Howerton believes the treatment should have no issue topping annual sales of 1 billion, reported BioPharma Dive. 